Antiviral therapy in liver transplant recipients: Is SVR the only endpoint that matters?

Journal of Hepatology

Volumn 46, Issue 3, 2007, Pages 359-361

  Kuo, Alexander ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ANTIVIRAL THERAPY; CYTOPENIA; DRUG WITHDRAWAL; EDITORIAL; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER GRAFT; LIVER TRANSPLANTATION; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; ENDPOINT DETERMINATION; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION; VIRUS REPLICATION;

EID: 33846632772     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.12.009     Document Type: Editorial

References (16)

1. Forman L.M., Lewis J.D., Berlin J.A., Feldman H.I., and Lucey M.R. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 (2002) 889-896
2. Berenguer M., Prieto M., San Juan F., Rayon J.M., Martinez F., Carrasco D., Moya A., Orbis F., Mir J., and Berenguer J. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36 (2002) 202-210
3. Wiesner R.H., Sorrell M., and Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 9 (2003) S1-S9
4. Fernandez I., Meneu J.C., Colina F., Garcia I., Munoz R., Castellano G., Fuertes A., Abradelo M., Lumbreras C., Moreno E., and Solis-Herruzo J.A. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 12 (2006) 1805-1812
5. Neumann U., Puhl G., Bahra M., Berg T., Langrehr J.M., Neuhaus R., and Neuhaus P. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 82 (2006) 43-47
6. Stravitz R.T., Shiffman M.L., Sanyal A.J., Luketic V.A., Sterling R.K., Heuman D.M., Ashworth A., Mills A.S., Contos M., Cotterell A.H., Maluf D., Posner M.P., and Fisher R.A. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 10 (2004) 850-858
7. Oton E., Barcena R., Moreno-Planas J.M., Cuervas-Mons V., Moreno-Zamora A., Barrios C., Garcia-Garzon S., Moreno A., Boullosa-Grana E., Rubio-Gonzalez E.E., Garcia-Gonzalez M., Blesa C., and Mateos M.L. Hepatitis C recurrence after liver transplantation: viral and histological response to full-dose peg-interferon and ribavirin. Am J Transplant 6 (2006) 2348-2355
8. Dumortier J., Scoazec J.Y., Chevallier P., and Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 40 (2004) 669-674
9. Samuel D., Bizollon T., Feray C., Roche B., Ahmed S.N., Lemonnier C., Cohard M., Reynes M., Chevallier M., Ducerf C., Baulieux J., Geffner M., Albrecht J.K., Bismuth H., and Trepo C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 124 (2003) 642-650
10. Chalasani N., Manzarbeitia C., Ferenci P., Vogel W., Fontana R.J., Voigt M., Riely C., Martin P., Teperman L., Jiao J., and Lopez-Talavera J.C. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41 (2005) 289-298
11. Abdelmalek M.F., Firpi R.J., Soldevila-Pico C., Reed A.I., Hemming A.W., Liu C., Crawford J.M., Davis G.L., and Nelson D.R. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 10 (2004) 199-207
12. Bizollon T., Pradat P., Mabrut J.Y., Chevallier M., Adham M., Radenne S., Souquet J.C., Ducerf C., Baulieux J., Zoulim F., and Trepo C. Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C. Am J Transplant 5 (2005) 1909-1913
13. Berenguer M., Prieto M., Palau A., Carrasco D., Rayon J.M., Calvo F., and Berenguer J. Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 16 (2004) 1207-1212
14. Giostra E., Kullak-Ublick G.A., Keller W., Fried R., Vanlemmens C., Kraehenbuhl S., Locher S., Egger H.P., Clavien P.A., Hadengue A., Mentha G., Morel P., and Negro F. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 17 (2004) 169-176
15. Mukherjee S., Lyden E., McCashland T.M., and Schafer D.F. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol 20 (2005) 198-203
16. Picciotto F.P., Tritto G., Lanza A.G., Addario L., De Luca M., Di Costanzo G.G., et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 46 (2007) 459-465